secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001437749-24-025650
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports Q2 net loss $1.7M, initiates 1-for-5 reverse split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Net loss for Q2 2024 was $1.7M ($0.10/sh) vs $2.2M ($0.16/sh) in Q2 2023; cash $7.1M sufficient through Aug 31, 2025.
- MNPR-101-Zr Phase 1 imaging trial initiated and enrolling; MNPR-101-RIT therapeutic trial on track to start Q4 2024.
- 1-for-5 reverse stock split effective Aug 12, 2024; shares reduce from ~17.6M to ~3.5M to regain Nasdaq compliance.
- Company winding down camsirubicin and MNPR-202 programs to focus on radiopharmaceutical platform.
- Needs additional funding within 12 months to further advance radiopharma programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/0001437749-24-025650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924025650/mnpr20240807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer